Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I dose-escalation study of tirabrutinib (ONO-4059) monotherapy in relapsed/refractory B-cell NHL and CLL
jRCT2080222631Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tirabrutinib in B-cell non-Hodgkin lymphoma (B-NHL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Ono Pharmaceutical. Started Oct 2014; status: completed.
02
Drugs
tirabrutinib
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on jRCT2080222631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222631.